LivaNova (LIVN) Cash from Operations Growth (3y) (2019 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn | 4.78% |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn | 9.30% |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn | 20.35% |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn | 22.35% |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn | -48.14% |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | 0.50% |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn | 50.11% |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn | -14.75% |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn | 15.83% |
| 10 | LivaNova | 4.03 Bn | 3.45 Bn | 243.75 Mn | -9.83% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -9.83% |
| Dec 31, 2025 | 63.93% |
| Sep 30, 2025 | 33.64% |
| Jun 30, 2025 | 101.18% |
| Mar 31, 2025 | -2.46% |
| Dec 31, 2024 | 32.97% |
| Sep 30, 2024 | 28.64% |
| Jun 30, 2024 | 19.15% |
| Mar 31, 2024 | -19.98% |
| Dec 31, 2023 | 13.42% |
| Sep 30, 2023 | 27.96% |
| Jun 30, 2023 | 1.93% |
| Mar 31, 2023 | 29.98% |
| Dec 31, 2022 | 86.87% |
| Sep 30, 2022 | 35.09% |
| Jun 30, 2022 | 19.17% |
| Mar 31, 2022 | 135.62% |
| Dec 31, 2021 | 17.03% |
| Sep 30, 2021 | -22.30% |
| Jun 30, 2021 | -3.07% |
| Mar 31, 2021 | -1.52% |
| Dec 31, 2020 | 27.91% |
| Sep 30, 2020 | -40.98% |
| Jun 30, 2020 | -126.03% |
| Mar 31, 2020 | -73.18% |
| Dec 31, 2019 | -58.74% |
| Sep 30, 2019 | -59.83% |
| Mar 31, 2019 | -40.98% |